Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 11.6% – What’s Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) rose 11.6% during mid-day trading on Thursday . The stock traded as high as $25.10 and last traded at $24.8950. Approximately 44,391 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 70,323 shares. The stock had previously closed at $22.31.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “neutral” rating and set a $20.00 price objective (up from $10.00) on shares of Lyell Immunopharma in a research note on Monday, November 24th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $20.00.

Lyell Immunopharma Trading Down 0.8%

The stock has a market capitalization of $535.81 million, a PE ratio of -1.10 and a beta of -0.11. The firm’s 50-day simple moving average is $18.43 and its two-hundred day simple moving average is $13.33.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. As a group, research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently bought and sold shares of LYEL. Millennium Management LLC lifted its position in Lyell Immunopharma by 140.0% during the 3rd quarter. Millennium Management LLC now owns 125,361 shares of the company’s stock worth $2,036,000 after acquiring an additional 73,132 shares during the last quarter. Foresite Capital Management V LLC grew its position in shares of Lyell Immunopharma by 17.3% in the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock valued at $7,748,000 after purchasing an additional 70,426 shares during the last quarter. ARCH Venture Management LLC increased its stake in shares of Lyell Immunopharma by 51.5% in the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after purchasing an additional 938,438 shares during the period. Two Sigma Investments LP lifted its position in shares of Lyell Immunopharma by 107.0% during the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock worth $338,000 after purchasing an additional 10,768 shares during the last quarter. Finally, Takeda Pharmaceutical Co. Ltd. lifted its position in shares of Lyell Immunopharma by 33.3% during the 3rd quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company’s stock worth $891,000 after purchasing an additional 13,722 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.